You have no items in your shopping cart.
You have no items in your shopping cart.
Catalog Number | orb1921848 |
---|---|
Category | Proteins |
Description | Interleukin-6 (IL-6) is a 26 kDa secreted protein that consists of 184 amino acids with two N-glycosylation sites and four cysteine residues. It is a pleiotropic cytokine with roles in immunity, tissue regeneration, and metabolism. Rapid production of IL-6 contributes to host defense during infection and tissue injury, but excessive synthesis of IL-6 and dysregulation of IL-6 receptor signaling is involved in disease pathology.Therapeutic agents targeting the IL-6 axis are effective in rheumatoid arthritis, and applications are being extended to other settings of acute and chronic inflammation. The IL-6 signaling cascade is initiated by binding of IL-6 to IL-6R and a second transmembrane protein, gp130, which serves as a signal transducer of IL-6. Although IL-6R expression is restricted to cells such as hepatocytes, monocytes, and lymphocytes, gp130 is ubiquitously expressed, potentially explaining the pleiotropic functions of IL-6. Unlike gp130, IL-6R exists in an 80 kDa transmembrane form and a 50-55 kDa soluble form (sIL-6R). Classic IL-6R signaling is thought to be anti-inflammatory and mediated by membrane-bound IL-6R (mIL-6R) and gp130. Classical IL-6 signaling only occurs on some subsets of T cells, hepatocytes, megakaryocytes, neutrophils and monocytes. Additionally, IL-6 can also bind to sIL-6R and the IL-6-sIL-6R complex then binds to membrane-bound gp130 on cells that do not express IL-6R on the surface, a process known as trans-signaling. In both classical and trans-signaling, the IL-6/IL-6R/gp130 complex activates intracellular signaling through the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway and the mitogen-activated protein kinase (MAPK) pathway. There is evidence that an imbalance away from the MAPK pathway via removal of regulation by suppressor of cytokine signaling 3 (SOCS3) towards the pro-inflammatory STAT3 signaling pathway contributes to autoimmune disease and therefore may also be a target for stress susceptibility. |
Form/Appearance | Lyophilized Powder |
Purity | ≥95% |
MW | 20.64 kDa |
Entrez | 3569 |
UniProt ID | P05231 |
Source | CHO Cell |
Expression System | Eukaryotic cell |
Endotoxins | ≤10 EU/mg |
Storage | Use a manual defrost freezer and avoid repeated freeze - thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month, 2 to 8°C under sterile conditions after reconstitution. 6 months, -20 to -74°C under sterile conditions after reconstitution. |
Alternative names | Interleukin 6, B-Cell Stimulatory Factor 2, B-Cell Read more... |
Note | For research use only |
Application notes | Application Notes: For research use only. Minimum Sample Size: 50μg/vial |
Expiration Date | 6 months from date of receipt. |
> 96% as determined by SDS-PAGE and HPLC. | |
20.7 kDa | |
E.Coli |
Greater than 95% as determined by SDS-PAGE. | |
20.9 kDa | |
E.coli |
ELISA, MS, SDS-PAGE, WB | |
Greater than 98% as determined by RP-HPLC and reducing SDS-PAGE. | |
E. coli |
ELISA, MS, SDS-PAGE, WB | |
Greater than 95% as determined by reducing SDS-PAGE. | |
Human cells |
Unconjugated | |
The purity of the protein is greater than 95% as determined by SDS-PAGE and Coomassie blue staining. | |
The protein has a predicted molecular mass of 47.9 kDa after removal of the signal peptide. The apparent molecular mass of mIL6-hFc is approximately 35-55 kDa due to glycosylation. | |
Mammalian |
Filter by Rating